Hodgkin Lymphoma News and Research RSS Feed - Hodgkin Lymphoma News and Research

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found. [More]
African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers. [More]
New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective. [More]
New study examines single 'transformer' proteins involved in cancer

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures. [More]
Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants. [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer. [More]
Many European hospitals fail to routinely test people at risk of HIV infection

Many European hospitals fail to routinely test people at risk of HIV infection

A new study reveals that many European hospitals fail to routinely test people who may be at risk of an HIV-infection. If tests were more widely offered in the healthcare system, fewer HIV-patients would go unnoticed, especially in Northern Europe. [More]
Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology, suggest the need for persistent cancer screening and prevention in these patients. [More]
Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma. [More]
Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. [More]
Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015. [More]
Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

Innovative immunotherapy clinical trial underway at The University of Kansas Cancer Center

A novel immunotherapy clinical trial underway now at The University of Kansas Cancer Center has enrolled the first patients in the world to receive what many doctors and researchers believe is the future of cancer treatment. [More]
Bacterium that causes Q fever associated with increased risk of lymphoma

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology. [More]
EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood. [More]
Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy. [More]
Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) - a rare type of non-Hodgkin lymphoma that affects the skin. [More]
Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group, one of India's leading generic pharmaceutical companies and one of the world's largest global producer of anti-retroviral drugs for HIV/AIDS treatment, today announces the successful launch of its biosimilar 'Rituximab' under the brand name MABALL in India. [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

FDA accepts Mundipharma EDO's Investigational New Drug Application for EDO-S101

Mundipharma EDO GmbH (Early Development in Oncology) is pleased to announce that the United States Food and Drug Administration has accepted the company's Investigational New Drug Application ("IND") for EDO-S101, a fusion molecule to treat relapsed/refractory haematologic malignancies and solid tumours. [More]
Advertisement
Advertisement